2Salminen S, Arvilommi H. Probiotics demonstrating efficacy in clinical settings[J]. Clin Infect Dis, 2001, 32:1577-1578.
3Saavedra JM. Clinical applications of probiotic agents[ J]. Am J Clin Nutr, 2001, 73 (6) :1147 -1151.
4Jutus KL, Silk JA. Quinoxaline N-oxides part Ⅳ: Derivatives of dyhydroxyalkyl and carboxy quinoxaline[J]. J Chem Soc 1955,1:2052 - 2058.
5Cihak R, Vontorkova M. Cytogenetic effects of quinoxaline-1,4-dioxide type growthpromoting agents Ⅲ. Transplacental micronucleus in mice[J]. Mutation research, 1985, 144(2) :81 -84.
6Sainz Y, Montoya ME, Martinez-Crespo FJ, et al. New quinoxaline 1,4 di-N-oxides for treatment of tuberculosis[ J]. AramzForsch, 1999, 49(1) :51 -59.
7.中华人民共和国国务院令第404号.兽药管理条例[S].[S].,..
8Mokhtar S, Behairr N, Sherbini E, et al. Qualitative and quantitative evaluation of aerobic microflora of the colon in biharzial patients before and after praziquantel therapy [ J ]. Egyptian J Bilhaziesis 1998, 10 (1): 111 -120.
10Shoop WL, Egerton JR, Eary CH, et al. Eprinomectin: a novel avemectin for use as a topical endectocide for cattle[ J]. International Journal Parasitology, 1996, 26 (11): 1237 - 1242.
